CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 50 enrolled
Drug / intervention
Squiddevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03524976
NCT03524976N/ACompleted
CompareCT.gov

LIQUID - Treatment of Dural Arteriovenous Fistulas With SQUID™ Liquid Embolic Agent, A Non-interventional, Observational, Prospective and Multi-center Study

Dr. Markus Alfred Möhlenbruch·observational·Posted May 15, 2018·Updated Oct 9, 2020

In Brief

An observational study evaluating Squid for Dural Arteriovenous Fistula. Completed, enrolled 50 participants across 7 sites.

Detailed Summary

The purpose of this study is assessment of safety, efficacy, and short-term outcome of SQUID™ in the embolization of Dural Arteriovenous Fistula

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsDural Arteriovenous Fistula
CountriesGermany
CollaboratorsUniversity Hospital Schleswig-Holstein

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedMay 15, 2018
Enrollment StartJan 1, 2017
Primary CompletionJul 30, 2020
Study CompletionAug 29, 2020
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 8.1 years ago

Interventions

Squiddevice

SQUID™ is injected into the vascular site to be treated, under fluoroscopic control. DMSO dissipates in the blood and causes precipitation of EVOH in which the tantalum powder is trapped. It then forms a consistent spongy embolus. This embolus solidifies from the outside inwardly while moving distally in the vessel. The non-adhesive character of the embolus allows slow and controlled injections while leaving in place the microcatheter.